On March 3, 2025 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, reported that its senior management will participate at upcoming investor conferences in the United States and Europe (Press release, Valneva, MAR 3, 2025, View Source;25.htm [SID1234650842]). CEO Thomas Lingelbach and CFO Peter Bühler will present at the TD Cowen 45th Annual Health Care Conference, taking place March 3 – 5, 2025, in Boston, MA. Mr. Lingelbach and Mr. Peter Bühler will also meet with institutional investors during the Van Lanschot Kempen Life Sciences Conference, held April 2 – 3, 2025, in Amsterdam, The Netherlands.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Management will discuss Valneva’s pipeline of potential first-in-class vaccine candidates, including its lead Lyme disease vaccine, VLA15, and its Shigella and Zika programs alongside the Company’s portfolio of marketed vaccines, which are expected to generate €170-180 million in revenue in 2025.
The TD Cowen presentation will be webcast live and available as a replay in the "investor" section of the Valneva website at www.valneva.com.
TD Cowen 45th Annual Health Care Conference
Date/Time: March 4, 1:10pm ET
Format: Presentation and investor meetings
Location: Boston, Massachusetts
Webcast Link: https://wsw.com/webcast/cowen177/vla/1855281
Van Lanschot Kempen Life Sciences Conference
Date/Time: April 3
Format: Investor meetings
Location: Amsterdam, The Netherlands
Attending institutional investors who would like to meet with Valneva management are asked to submit a request to their representative at the respective bank.